SPTBN1 and cancer, which links?

Chen, Shuyi; Li, Jiajia; Zhou, Ping; Zhi, Xiuling

doi:10.1002/jcp.28975

Cited by 24 publications

(27 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, the changes of βII spectrin in clinical diseases cannot be ignored. As mentioned above, previous studies have also demonstrated that SPTBN1 was down-regulated in a variety of cancers, such as hepatocellular carcinoma, gastrointestinal tumors and lung cancer 10,30,69 . At the same time, its expression level is closely related to the patient's prognosis, such as hepatocellular carcinoma, pancreatic cancer and lung cancer 61,66,72,73,102 .…”

Section: The Potential Of βIi Spectrin (Sptbn1) As a Therapeutic Targetmentioning

confidence: 68%

“…Notably, the versatile role of βII spectrin in disease has been reported in an increasing numbers of studies, and βII spectrin has been implicated in diseases such as cancer, neurological disorders, cardiovascular diseases, osteoporosis, and hearing loss 2,[10][11][12][13] . Strikingly, growing evidence associates βII spectrin with various cancers, and expression and function vary between different tumor stages or types of βII spectrin 10 . Moreover, the most serious effect was observed in mice deficient in βII spectrin, which caused embryonic lethality 14 .…”

Section: Ivyspringmentioning

confidence: 99%

“…4, Table 1) 30,[69][70][71] . TGF-β/Smad, Wnt/β-catenin, Notch, NF-κB, IL-6/transcription 3 (STAT3) and other signaling pathways are now known to be important in the relationship between βII spectrin and cancer 10 . This raises the possibility that βII spectrin can be used as a diagnostic biomarker and for a molecular assessment of prognosis.…”

Section: The Involvement Of βIi Spectrin In Cancermentioning

confidence: 99%

See 2 more Smart Citations

βII spectrin (SPTBN1): biological function and clinical potential in cancer and other diseases

Yang¹,

Yang²,

Sun³

et al. 2021

Int. J. Biol. Sci.

View full text Add to dashboard Cite

βII spectrin, the most common isoform of non-erythrocyte spectrin, is a cytoskeleton protein present in all nucleated cells. Interestingly, βII spectrin is essential for the development of various organs such as nerve, epithelium, inner ear, liver and heart. The functions of βII spectrin include not only establishing and maintaining the cell structure but also regulating a variety of cellular functions, such as cell apoptosis, cell adhesion, cell spreading and cell cycle regulation. Notably, βII spectrin dysfunction is associated with embryonic lethality and the DNA damage response. More recently, the detection of altered βII spectrin expression in tumors indicated that βII spectrin might be involved in the development and progression of cancer. Its mutations and disorders could result in developmental disabilities and various diseases. The versatile roles of βII spectrin in disease have been examined in an increasing number of studies; nonetheless, the exact mechanisms of βII spectrin are still poorly understood. Thus, we summarize the structural features and biological roles of βII spectrin and discuss its molecular mechanisms and functions in development, homeostasis, regeneration and differentiation. This review highlight the potential effects of βII spectrin dysfunction in cancer and other diseases, outstanding questions for the future investigation of therapeutic targets. The investigation of the regulatory mechanism of βII spectrin signal inactivation and recovery may bring hope for future therapy of related diseases.

show abstract

Section: The Potential Of βIi Spectrin (Sptbn1) As a Therapeutic Targetmentioning

confidence: 68%

Section: Ivyspringmentioning

confidence: 99%

Section: The Involvement Of βIi Spectrin In Cancermentioning

confidence: 99%

See 1 more Smart Citation

βII spectrin (SPTBN1): biological function and clinical potential in cancer and other diseases

Yang¹,

Yang²,

Sun³

et al. 2021

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

“…SPTBN1 can regulate the cell cycle and EMT through TGF-β and Wnt/β-catenin signaling pathways, thus regulating the proliferation and migration of hepatocellular carcinoma. In addition, SPTBN1 can play an anticancer role by regulating apoptosis, DNA damage repair and angiogenesis [31]. In EOC, it was reported that SPTBN1 contributed to platinum resistance by forming a spectrin-GS-pt complex [18].…”

Section: Discussionmentioning

confidence: 99%

SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway

Chen

Zeng

Chen

et al. 2020

Aging

Self Cite

View full text Add to dashboard Cite

SPTBN1 plays an anticancer role in many kinds of tumors and participates in the chemotherapeutic resistance of epithelial ovarian cancer (EOC). Here, we reported that lower SPTBN1 expression was significantly related to advanced EOC stage and shorter progression-free survival. SPTBN1 expression was also higher in less invasive EOC cell lines. Moreover, SPTBN1 decreased the migration ability of the EOC cells A2780 and HO8910 and inhibited the growth of EOC cells in vitro and tumor xenografts in vivo. SPTBN1 suppression increased the epithelial mesenchymal transformation marker Vimentin while decreasing E-cadherin expression. By analyzing TCGA data and immunohistochemistry staining of tumor tissue, we found that SPTBN1 and SOCS3 were positively coexpressed in EOC patients. SOCS3 overexpression or JAK2 inhibition decreased the proliferation and migration of EOC cells as well as the expression of p-JAK2, p-STAT3 and Vimentin, which were enhanced by the downregulation of SPTBN1, while E-cadherin expression was also reversed. It was also verified in mouse embryonic fibroblasts (MEFs) that loss of SPTBN1 activated the JAK/STAT3 signaling pathway with suppression of SOCS3. Our results suggest that SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3mediated blockade of the JAK/STAT3 signaling pathway.

show abstract

“…The aim of the present study was to reanalyze an existing dataset in order to see if novel genes could be found. Microarray data analysis, filtering and feature selection revealed that COL10A1, SPOCK2, SPTBN1, RTKN2, FUT2 and AGER differentially expressed genes may be potentially involved in NSCLC and many other studies have demonstrated the same result [21][22][23][24][25][26][27]. COL10A1 [22] was identified to be common to all three algorithms, suggesting that it could be a gene that may play an important role in NSCLC.…”

Section: Discussionmentioning

confidence: 89%

Reanalysis of Non-Small-Cell Lung Cancer Microarray Gene Expression Data

Bawa

Özkan²,

Erol

2021

The 7th International Management Information Systems Conference

View full text Add to dashboard Cite

Cancer is one of the leading causes of death in many countries, and this continues to be the case because of the lack of sufficient treatment. One of the most common types is non-small-cell lung cancer (NSCLC). The increasingly large and diverse public datasets about NSCLC constitute a rich source of data on which several analyses can be performed so as to find candidate oncogenic drivers or therapeutic targets. The aim of this study is to reanalyze an existing NSCLC NCBI GEO Dataset (accession = GSE19804) in order to see if novel involved genes can be found. For this, we used microarray technology for preprocessing and, based on random forest, support vector machine and C5.0 decision tree models, made a comparison of the 10 most important genes recorded. This study was realized with R-Studio 4.0.2 and Bioconductor 3.11. In conclusion, the EFNA4 gene and other genes, namely KANK3, GRK5, CLIC5, SH3GL3, ACACB, LIN7A, JCAD, and NEDD1, are thought to be potential genes that may play a role in NSCLC and it is recommended that researchers working in the wet laboratory should focus on these genes.

show abstract

SPTBN1 and cancer, which links?

Cited by 24 publications

References 56 publications

βII spectrin (SPTBN1): biological function and clinical potential in cancer and other diseases

βII spectrin (SPTBN1): biological function and clinical potential in cancer and other diseases

SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway

Reanalysis of Non-Small-Cell Lung Cancer Microarray Gene Expression Data

Contact Info

Product

Resources

About